Literature DB >> 12573770

Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.

Zhe Chen1, Ravinder Nath.   

Abstract

PURPOSE: To develop a tool for evaluating interstitial seed implants that contain a mixture of radionuclides with different half-lives and to demonstrate its utility by examining the clinical implications of prescribing to an isodose surface for such an implant. METHODS AND MATERIALS: A linear-quadratic model for continuous low dose rate irradiation was developed for permanent implants containing a mixture of radionuclides. Using a generalized equation for the biologically effective dose (BED), the effects of cell proliferation and sublethal damage repair were examined systematically for implants containing a mixture of radionuclides. A head-and-neck permanent seed implant that contained a mixture of (125)I and (103)Pd seeds was used to demonstrate the utility of the generalized BED.
RESULTS: An equation of BED for implants containing a mixture of radionuclides with different half-lives was obtained. In such an implant, the effective cell kill was shown to depend strongly on the relative dose contributions from each radionuclide type; dose delivered by radionuclides with shorter half-life always resulted in more cell kill for any given sublethal damage repair and cell proliferation rates. Application of the BED formula to an implant containing a mixture of (125)I and (103)Pd seeds demonstrates that the conventional dose prescription to an isodose surface is not unique for such an implant. When the prescription dose was based on existing clinical experience of using (125)I seeds alone, mixing (103)Pd seeds with (125)I seeds would increase the cell kill. On the other hand, if the prescription dose were based on existing clinical experience of using (103)Pd seeds alone, mixing (125)I seeds with (103)Pd seeds in the same implant would create radiobiologically "cold" spots (i.e., an increase in cell survival) at locations where a major portion of the prescription dose is contributed by the (125)I seeds. For fast-growing tumors, these "cold" spots can become significant.
CONCLUSIONS: Total dose alone is no longer sufficient for a complete characterization of a permanent seed implant containing a mixture of radionuclides with different half-lives due to the presence of cell proliferation and sublethal damage repair in the protracted dose delivery. BED provides a tool for evaluating the radiobiologic effects of mixing different type of radionuclides in the same implant. When radionuclides of different half-lives are mixed in a permanent implant, using the dose prescription established from existing clinical experience of implants with the longer half-life radionuclide would help to avoid radiobiologic "cold" spots.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573770     DOI: 10.1016/s0360-3016(02)04282-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.

Authors:  Ravinder Nath; William S Bice; Wayne M Butler; Zhe Chen; Ali S Meigooni; Vrinda Narayana; Mark J Rivard; Yan Yu
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

2.  The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers.

Authors:  Zhe Jay Chen; Kenneth Roberts; Roy Decker; Pradip Pathare; Sara Rockwell; Ravinder Nath
Journal:  Phys Med Biol       Date:  2011-07-19       Impact factor: 3.609

3.  Computed tomography-guided implantation of 125I radioactive seeds in patients with malignant airway compression induced by advanced lung cancer: effectiveness and safety in 40 patients.

Authors:  Zhiyou Zhao; Wang Yao; Tao Zhang; Shixin Chen; Wei Fu; Lijun Chen; Yonggang Ma; Jianzhuang Wang; Mingjian Lu; Dechao Jiao
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

4.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

5.  Treatment planning considerations for 125I eye plaque brachytherapy.

Authors:  David Miguel; Jesús María de Frutos; Francisco López-Lara; Pilar Alonso; Patricia Diezhandino; María Antonia Saornil; Ciro García
Journal:  J Contemp Brachytherapy       Date:  2019-06-28

6.  Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion.

Authors:  Honglai Zhang; Lin Wang; Adam C Riegel; Jeffrey Antone; Louis Potters; Lucille Lee; Yijian Cao
Journal:  J Appl Clin Med Phys       Date:  2022-03-14       Impact factor: 2.243

Review 7.  Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review.

Authors:  Zongyan Shen; Ang Qu; Ping Jiang; Yuliang Jiang; Haitao Sun; Junjie Wang
Journal:  Curr Oncol       Date:  2022-07-25       Impact factor: 3.109

8.  Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy.

Authors:  Jakub Pritz; Kenneth M Forster; Amarjit S Saini; Matthew C Biagioli; Geoffrey G Zhang
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102

9.  A Novel Tracheobronchial Stent Loaded with 125I Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study.

Authors:  Yong Wang; Jian Lu; Jin-He Guo; Guang-Yu Zhu; Hai-Dong Zhu; Li Chen; Chao Wang; Gao-Jun Teng
Journal:  EBioMedicine       Date:  2018-06-14       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.